PET/MR bests PET/CT in identifying prostate cancer recurrence

06/21/2013 | Medscape (free registration)

PET/MR imaging with 11C-choline for restaging of prostate cancer was well-tolerated and able to identify more small local recurrences than PET/CT, according to a study presented at the SNMMI Annual Meeting. The radiation dose exposure with PET/MR imaging is about 80% lower than with PET/CT, researchers said, suggesting the approach may be particularly beneficial for patients who need a number of tests.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX